It depends on your state. Federal law lets each state Medicaid program exclude drugs “when used for anorexia, weight loss, or weight gain” [1]. Some states use that exclusion, and others cover the drugs, some of them with restrictions. In one health system, 8.0% of 50,678 adults with obesity were prescribed a weight-loss drug and 4.4% filled one [4]. Medicaid coverage was linked with lower odds of both [4].
This page covers Medicaid only. Medicare runs on a different statutory rule, which is set out in whether Medicare covers Ozempic and Wegovy. Employer and marketplace plans follow their own terms, covered in what decides your bill.
Rule one: the exclusion is optional
The rule sits in section 1927 of the Social Security Act, in a list of drug uses a state may exclude from coverage or restrict. The first entry reads: “Agents when used for anorexia, weight loss, or weight gain” [1]. The operative word is may, which makes the exclusion a state choice. A state that uses the exclusion does not cover these drugs for weight. A state that does not use it is free to cover them.
That is why the answer changes at a state line. An analysis of 2023 pharmacy claims sorted each state’s Medicaid coverage into three groups: “not covered,” “restricted,” or “unrestricted” [2]. Use was nominally higher in the restricted and unrestricted states than in the not-covered ones [2]. Each state publishes its own drug list, and that list settles the answer for one state.
Rule two: the exclusion names a use, not a drug
The statute excludes agents “when used for” weight loss, and it does not name semaglutide or tirzepatide [1]. A prescription written for type 2 diabetes is not a weight-loss use, so the exclusion’s words do not reach it.
The same claims study measured diabetes use separately. In Medicaid, state use for diabetes tracked diabetes prevalence only weakly, while in commercial plans the link was strong [2]. Use for obesity showed weak or negligible links to obesity rates in every payer group [2]. In Medicaid, how common a condition was in a state said little about how often the drug was used there.
A label decides which use a prescription is. Ozempic and Mounjaro carry diabetes labels, while Wegovy and Zepbound carry weight labels. How that split works is in whether Wegovy is the same as Ozempic.
Rule three: coverage can carry conditions
The statute’s first permitted restriction reads: “A State may subject to prior authorization any covered outpatient drug” [1]. A covered drug is therefore not an automatic fill. The state sets the criteria, the prescriber submits the evidence, and the state approves or denies the request.
Massachusetts shows one version. A study of MassHealth, its Medicaid program, followed 7,493 adults who started Wegovy or Zepbound between July and December 2024 [3]. At six months, 60.8% were persistent, meaning no more than 56 days between fills [3]. Adherence, measured as at least 80% of days covered, was 60.1% [3].
Weight was documented at the six-month prior-authorization recertification. In a subgroup of persistent, adherent members, 86.5% had lost at least 5% by then [3]. Lower persistence was linked with male sex, age under 40, diabetes and having no weight-related conditions [3]. Recertification is the point where coverage is kept or lost.
What insurance type does to a prescription
One health system in Ohio and Florida followed a cohort of 50,678 adults with a BMI of 30 or more [4]. Only 8.0% received a prescription for a weight-loss drug, and only 4.4% filled one [4]. Against private insurance, Medicaid was linked with lower odds of a new prescription and with lower odds of a fill [4].
That cohort ran from 2015 to 2023 and included older drugs. It shows an association with insurance type, not the effect of any state’s policy. The wider pattern of who gets a prescription is in semaglutide use by income and insurance. The reasons people give for going without are in why people cannot get a prescription.
When the answer is a denial
A denial traces back to one of the three rules above. Either the state excludes weight-loss use, or the request did not meet the prior-authorization criteria, or the prescription named a use the state does not cover. The first is a state policy, not a clinical judgment. The second turns on documentation the prescriber submits. How long a review takes is in how long prior authorization takes.
A reader outside coverage pays cash for the drug. Compounded semaglutide and tirzepatide are sold in that market and are not FDA-approved. What a month costs across the cash market is in what a GLP-1 costs per month.